GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Huapont Life Science Co Ltd (SZSE:002004) » Definitions » Cash Flow from Financing

Huapont Life Science Co (SZSE:002004) Cash Flow from Financing : ¥407 Mil (TTM As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Huapont Life Science Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2024, Huapont Life Science Co paid ¥0 Mil more to buy back shares than it received from issuing new shares. It spent ¥378 Mil paying down its debt. It paid ¥0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent ¥83 Mil paying cash dividends to shareholders. It received ¥101 Mil on other financial activities. In all, Huapont Life Science Co spent ¥360 Mil on financial activities for the three months ended in Sep. 2024.


Huapont Life Science Co Cash Flow from Financing Historical Data

The historical data trend for Huapont Life Science Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huapont Life Science Co Cash Flow from Financing Chart

Huapont Life Science Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,627.76 -239.57 -203.77 -1,370.26 -3.66

Huapont Life Science Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -285.69 461.08 731.47 -425.17 -360.16

Huapont Life Science Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Huapont Life Science Co's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Huapont Life Science Co's Cash from Financing for the quarter that ended in Sep. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥407 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Huapont Life Science Co  (SZSE:002004) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Huapont Life Science Co's issuance of stock for the three months ended in Sep. 2024 was ¥0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Huapont Life Science Co's repurchase of stock for the three months ended in Sep. 2024 was ¥0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Huapont Life Science Co's net issuance of debt for the three months ended in Sep. 2024 was ¥-378 Mil. Huapont Life Science Co spent ¥378 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Huapont Life Science Co's net issuance of preferred for the three months ended in Sep. 2024 was ¥0 Mil. Huapont Life Science Co paid ¥0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Huapont Life Science Co's cash flow for dividends for the three months ended in Sep. 2024 was ¥-83 Mil. Huapont Life Science Co spent ¥83 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Huapont Life Science Co's other financing for the three months ended in Sep. 2024 was ¥101 Mil. Huapont Life Science Co received ¥101 Mil on other financial activities.


Huapont Life Science Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Huapont Life Science Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Huapont Life Science Co Business Description

Traded in Other Exchanges
N/A
Address
No. 69, Renhe Xingguang Avenue, Yubei District, Chongqing, CHN, 401121
Huapont Life Science Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. In addition, the company is also engaged in the agrochemical business and medical business. The agrochemical department is mainly engaged in the research and development, production, sales, and technical services of pesticide intermediates, original drugs, and preparations.
Executives
Zhang Hai An Directors, executives
Wang Rong Director
Yu Jun Tian Director
Zhang Song Shan Directors, executives
Chen Zhi Securities Affairs Representative
Jiang Kang Wei Director
Lv Li Ming Director
Li Sheng Xue Director
Luo Da Lin Supervisors
Li Zhi Directors, executives
Tian Song Min Executives
Wu Bi Zhong Director
Yu Yun Jian Supervisors
Gu Chuan Wei Supervisors

Huapont Life Science Co Headlines

No Headlines